GlassScriptPhysician profile
Carrie V Eugster
NPI 1336370626
$795.03
in general payments reported to CMS, 2019-2025
12 companies · $172 in 2025
The $172 reported for 2025 was less than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $158 · 2022: $184 · 2023: $98.49 · 2024: $182 · 2025: $172.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $452.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $452.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $157.71 | 2021-2025 | Mounjaro, Zepbound |
| Novo Nordisk INC | $150.88 | 2021-2024 | Wegovy, Ozempic, Rybelsus |
| Abbvie INC. | $112.84 | 2022-2024 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $75.22 | 2024-2025 | Caplyta |
| Gilead Sciences, INC. | $66.01 | 2022 | |
| Exact Sciences Corporation | $64.40 | 2023-2025 | Cologuard Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $45.02 | 2021 | |
| Nestle Healthcare Nutrition INC. | $38.33 | 2021 | |
| Axsome Therapeutics, INC. | $30.78 | 2025 | Auvelity |
| Glaxosmithkline, LLC. | $23.93 | 2024 | Trelegy Ellipta |
| Amgen INC. | $16.49 | 2025 | Otezla, Repatha |
| Supernus Pharmaceuticals, INC. | $13.42 | 2024 | Qelbree |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carrie Eugster listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.